/PRNewswire/ Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class.
Two new biotech companies launched today: NextRNA to focus on non-coding RNA technology, and Pathalys, with a clinic-ready licensed compound and plans to enter Phase III trials.